Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Vera Therapeutics
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
July 9, 2026
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
July 7, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 5, 2026
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
June 2, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2026
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
May 8, 2026
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
May 4, 2026
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 27, 2026
1
2
Next Page
→